The Association Between MGP Gene Polymorphisms and Coronary Artery Disease

Abstract

Objectives: Coronary artery calcification (CAC) is associated with coronary atherosclerosis. There is a significant relation between coronary artery wall calcification and coronary artery disease (CAD). The measure of coronary artery calcification is an indicator of subclinical atherosclerosis. In some studies, it has been shown that coronary artery calcification is independent from conventional cardiovascular risks, which suggests data about prognosis. Matrix Gla protein (MGP) is an important protective modulator against calcification since it is an inhibitor of tissue calcification. In this respect, we aimed to establish the relationship between the distributions of nucleotide alterations found in promoter and coding regions of the MGP gene in patients with CAD and patients with normal coronary. Methods: DNA samples (n=115) were obtained from 58 patients with CAD and 57 healthy controls. The DNA samples obtained were analyzed by a Polymerase Chain Reaction (PCR) method using three sets of primer pairs, which cover the coding (Thr83Ala in exon 4) and promoter regions (T-138C and G-7A) of the MGP gene. Amplified regions were analyzed by a Restriction Fragment Length Polymorphism (RFLP) method for possible polymorphisms. Results: The chi-square analysis of the results revealed that there is no relationship between the observed polymorphisms and CAD. Conclusions: In this study, we investigated the relationship between MGP gene polymorphism and CAD. However, according to our findings, there was no statistically significant difference between the CAD and the control group. 

Keywords

• Coronary artery disease,vascular calcification,matrix Gla Protein,genetic polymorphism

References

1. 1. Ross R. Atherosclerosis -an inflammatory disease. N Engl J Med 1999;340:115-126.
2. 2. Mintz GS, Popma JJ, Pichard AD, et al.Patterns of calcification in coronary artery disease. A statistical analysis of intravascular ultrasound and coronary angiography in 1155 lesions. Circulation 1995;91:1959-1965.
3. 3. Watson KE. Pathophysiology of coronary calcification. J Cardiovasc Risk 2000;7:93-97.
4. 4. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation 1996;94:1175-1192.
5. 5. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation 1995; 92:2157-2162.
6. 6. Doherty TM, Detrano RC. Coronary arterial calcification as an active process: a new perspective on an old problem. Calcif Tissue Int 1994;54:224-230.
7. 7. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-942.
8. 8. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-1740.

9. 9. Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: intima versus media. Herz 2001;26:245-251.
10. 10. Kurabayashi M. Vascular Calcification - Pathological Mechanism and Clinical Application - Role of vascular smooth muscle cells in vascular calcification. Clin Calcium 2015; 25:661-669.
11. 11. Proudfoot D, Skepper JN, Shanahan CM, Weissberg PL. Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol 1998;18:379-388.
12. 12. Cancela L, Hsieh CL, Francke U, Price PA. Molecular structure, chromosome assignment, and promoter organization of the human matrix Gla protein gene. J Biol Chem 1990; 265:15040-15048.
13. 13. Worcester EM. Inhibitors of stone formation. Semin Nephrol 1996;16:474-486.
14. 14. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
15. 15. Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet 1999;354:1234-1241.
16. 16. Gassett AJ, Sheppard L, McClelland RL,et al. Risk Factors for Long-Term Coronary Artery Calcium Progression in the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc 2015;4(8).
17. 17. Raggi P, Callister TQ, Shaw LJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol 2004;24:1272-1277.
18. 18. Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. J Thromb Haemost 2008;100:593-603.
19. 19. Price PA, Williamson MK, Haba T, Dell RB, Jee WS. Excessive mineralization with growth plate closure in rats on chronic warfarin treatment. Proc Natl Acad Sci USA 1982;79:7734-7738.
20. 20. Howe AM, Webster WS. The warfarin embryopathy: a rat model showing maxillonasal hypoplasia and other skeletal disturbances. Teratology 1992;46:379-390.
21. 21. Hale JE, Fraser JD, Price PA. The identification of matrix Gla protein in cartilage. J Biol Chem 1988;263:5820-5824. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78-81.
22. 23. Sweatt A, Sane DC, Hutson SM, Wallin R. Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J Thromb Haemost 2003;1:178-185.
23. 24. Huang H, Virmani R, Younis H, Burke AP, Kamm RD, Lee RT. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation 2001;103:1051-1056.
24. 25. Farzaneh-Far A, Davies JD, Braam LA, et al. A polymorphism of the human matrix gammacarboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem 2001;276:32466-32473.
25. 26. Herrmann SM, Whatling C, Brand E, et al. Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol 2000;20:2386-2393.
26. 27. Brancaccio D, Biondi ML, Gallieni M, et al. Matrix GLA protein gene polymorphisms: clinical correlates and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol 2005;25:548-552.
27. 28. Cassidy-Bushrow AE, Bielak LF, Levin AM, et al. Matrix gla protein gene polymorphism is associated with increased coronary artery calcification progression. Arterioscler Thromb Vasc Biol 2013;33:645-651.
28. 29. Garbuzova VY, Gurianova VL, Stroy DA, Dosenko VE, Parkhomenko AN, Ataman AV. Association of matrix Gla protein gene allelic polymorphisms (G(-7)-->A, T(-138)-->C and Thr(83)-->Ala) with acute coronary syndrome in the Ukrainian population. Exp Clin Cardiol 2012;17:30-33.
29. 30. Najafi M, Roustazadeh A, Amirfarhangi A, Kazemi B. Matrix Gla protein (MGP) promoter polymorphic variants and its serum level in stenosis of coronary artery. Mol Biol Rep 2014;41:1779-1786.